NCT05800964 2026-02-17
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
Clinical Trials
128 trialsNCT05864573 2026-01-05
Study of ZGGS15 in Patients With Advanced Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1 Completed
NCT05240898 2025-12-18
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT05287399 2025-12-18
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors
Ascletis Pharma Inc
Phase 1 Completed
NCT05105971 2025-12-08
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China
Bio-Thera Solutions
Phase 1 Completed
NCT05387928 2025-12-05
A Study of KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT05549804 2025-12-05
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Completed
NCT04362748 2025-10-07
Study of AMG 256 in Adult Subjects With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT04446260 2025-09-15
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT05063318 2025-09-02
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05494918 2025-08-22
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Alphamab (Australia) Co Pty Ltd.
Phase 1 Completed
NCT05685472 2025-08-08
MEDI5752 in Japanese Patients With Advanced Solid Tumors.
AstraZeneca
Phase 1 Completed
NCT03853109 2025-07-20
AMG 404 in Patients With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT05487235 2025-07-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT06381050 2025-06-13
The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Completed
NCT00529438 2025-05-28
RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies
Biogen
Phase 1 Completed
NCT04972981 2025-05-22
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Phase 1 Completed
NCT03544905 2025-04-22
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Haihe Biopharma Co., Ltd.
Phase 1 Completed
NCT04882917 2025-03-07
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
EMD Serono
Phase 1 Completed
NCT06012708 2025-01-08
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
New Cancer Cure-Bio Co.,Ltd.
Phase 1 Completed
NCT04727554 2025-01-06
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
Amgen
Phase 1 Completed
NCT02456883 2024-11-05
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Completed
NCT03666143 2024-11-04
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeiGene
Phase 1 Completed
NCT02516813 2024-10-15
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
EMD Serono
Phase 1 Completed
NCT03744403 2024-09-19
A Study of CS1001 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1 Completed
NCT04087018 2024-09-19
Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors
Arcus Biosciences, Inc.
Phase 1 Completed
NCT01867866 2024-09-05
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
Phase 1 Completed
NCT02031055 2024-09-05
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT02454062 2024-09-04
A Trial of TAS-114 in Combination With S-1
Taiho Oncology, Inc.
Phase 1 Completed
NCT06172309 2024-07-29
A Phase I Study of NTQ1062 in Chinese Patients With Advanced Solid Tumors
Nanjing Chia-tai Tianqing Pharmaceutical
Phase 1 Completed
NCT05731934 2024-06-18
The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1 Completed
NCT02261285 2024-05-06
ONO-4538 Phase I Study in Patients With Solid Tumor
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT05498480 2024-02-20
RELATIVITY-111
Bristol-Myers Squibb
Phase 1 Completed
NCT00782574 2023-12-21
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
AstraZeneca
Phase 1 Completed
NCT03463473 2023-12-18
A Phase I Study of MSB2311 in Advanced Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1 Completed
NCT05017623 2023-11-18
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT01773421 2023-06-22
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01009190 2023-06-08
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
pharmaand GmbH
Phase 1 Completed
NCT04911881 2023-03-01
A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04911894 2023-03-01
A Study of Dose Escalation of IBI321 in Patients With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02721589 2023-02-28
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03545971 2023-02-28
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03889275 2023-02-21
A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors
MedImmune LLC
Phase 1 Completed
NCT03901950 2023-02-16
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
Evopoint Biosciences Inc.
Phase 1 Completed
NCT02197572 2023-01-23
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT04659096 2022-12-21
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
Ionis Pharmaceuticals, Inc.
Phase 1 Completed
NCT04699929 2022-12-12
A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1 Completed
NCT03934359 2022-11-18
A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors
Shanghai De Novo Pharmatech Co., Ltd.
Phase 1 Completed
NCT04261075 2022-08-15
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
MedImmune LLC
Phase 1 Completed
NCT00419328 2022-07-21
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
AGC Biologics S.p.A.
Phase 1 Completed